A Potential Shift In FDA's Approach To Drug Trial Design
By Jessica Ritsick, Yifan Wang and Barbara Jones-Binns · February 19, 2026, 5:54 PM EST
On Jan. 9, the U.S. Food and Drug Administration issued a draft guidance document, "Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products," which clarifies how Bayesian approaches may be...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login